Group 1 - The core point of the article is that Huiyu Pharmaceutical reported a decline in both revenue and net profit for the third quarter and the first three quarters of the year [1] Group 2 - For the third quarter, the company's revenue was 289 million yuan, a year-on-year decrease of 9.70% [1] - The net profit for the third quarter was 29.92 million yuan, reflecting a significant year-on-year decline of 81.55% [1] - For the first three quarters, the total revenue was 742 million yuan, which represents a year-on-year decrease of 12.92% [1] - The net profit for the first three quarters was -50.80 million yuan, indicating a year-on-year decline of 122.35% [1]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-083 四川汇宇制药股份有限公司 关于自愿披露公司参与全国药品集中采购拟中选的公告 本次公司拟中选的产品于 2024 年 10 月获得国家药品监督管理局签发的《药 品注册证书》，本次中标前暂未产生销售收入。 本次集中采购是国家组织的第十一批药品集中带量采购，采购周期中，医疗 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）全资子公司四川汇宇海玥 医药科技有限公司参与了国家组织药品联合采购办公室（以下简称"联采办"） 组织的第十一批全国药品集中采购的投标工作，根据联采办于 2025 年 10 月 28 日在上海阳光医药采购网（https://www.smpaa.cn）发布的《全国药品集中采购拟 中选结果公示》显示，公司 1 个产品拟中标本次集中采购，现将相关情况公告如 下： | 序 | 拟中选 | 适应症 | 包装 | 计价 | 拟中选 | 采购周期 | | | --- | --- | --- | --- | --- ...

Core Viewpoint - The company, Huilong Pharmaceutical, announced its subsidiary's participation in the 11th national centralized drug procurement organized by the National Drug Procurement Office, with one product, Meisobam Injection, expected to win the bid [1] Group 1 - The company’s subsidiary, Sichuan Huilong Haiyue Pharmaceutical Technology Co., Ltd., is involved in the bidding process for centralized drug procurement [1] - The product Meisobam Injection is anticipated to be awarded in this procurement round [1] - The product is expected to receive its drug registration certificate from the National Medical Products Administration in October 2024, and has not generated any sales revenue prior to this bid [1]

Core Points - The stock of Huayu Pharmaceutical (688553.SH) closed at 21.28 yuan, reflecting a decline of 2.96% and is currently in a state of breaking below its initial public offering price [1] - Huayu Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1] - On the first day of trading, the stock reached a peak of 42.59 yuan, marking the highest price since its listing [1] - The total funds raised from the IPO amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, which was 453 million yuan more than the original plan [1] - The company intended to raise 1.907 billion yuan for projects including the construction of a second phase of the EU-standard injection production base and the establishment of an innovative drug research institute, as well as to supplement working capital [1] - The total issuance costs were 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities amounting to 98.875 million yuan [1]

Core Points - Huiyu Pharmaceutical (688553.SH) closed at 21.28 yuan, with a decline of 2.96%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering (IPO) of 63.6 million shares at a price of 38.87 yuan per share [1] - On the first day of trading, the stock reached a peak of 42.59 yuan, marking the highest price since its listing [1] Fundraising and Financials - Huiyu Pharmaceutical raised a total of 2.472 billion yuan through the IPO, with a net amount of 2.361 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 453 million yuan [1] - The company intended to use the funds for the construction of the EU-standard injection production base (Phase II), the establishment of an innovative drug research institute, and to supplement working capital [1] - Total issuance costs amounted to 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities totaling 98.875 million yuan [1]

Core Points - On October 23, Huayu Pharmaceutical experienced a decline of 5.02%, trading at 20.83 CNY per share, with a transaction volume of 75.7042 million CNY and a turnover rate of 1.04%, resulting in a total market capitalization of 8.824 billion CNY [1] - Huayu Pharmaceutical, established on October 12, 2010, and listed on October 26, 2021, focuses on the research, production, and domestic and international sales of oncology drugs and complex injectable drugs [1] - The company's revenue composition is primarily from drug sales (97.27%), followed by technical services (1.66%) and other sources (1.07%) [1] Fund Holdings - According to data, Yongying Fund holds a significant position in Huayu Pharmaceutical through its fund Yongying Medical Health A (008618), which held 219,600 shares in the second quarter, accounting for 3.56% of the fund's net value, ranking as the tenth largest holding [2] - The fund, established on May 20, 2020, has a latest scale of 24.1775 million CNY, with a year-to-date return of 14.74% and a one-year return of 12.38%, ranking 3177 out of 4218 and 2997 out of 3875 in its category, respectively [2] - The fund manager, Shan Lin, has been in the position for 1 year and 125 days, overseeing total assets of 3.143 billion CNY, with the best fund return during his tenure being 103.91% and the worst being 13.89% [2]

Group 1 - The core point of the news is that Sichuan Huiyu Pharmaceutical Co., Ltd. experienced a stock decline of 5.24%, with a current share price of 19.90 yuan and a total market capitalization of 8.43 billion yuan [1] - The company was established on October 12, 2010, and went public on October 26, 2021, focusing on the research, production, and sales of oncology drugs and complex injectable drugs [1] - The main revenue composition of the company includes 97.27% from drug sales, 1.66% from technical services, and 1.07% from other sources [1] Group 2 - From the perspective of fund holdings, Dachen Fund has a significant position in Huiyu Pharmaceutical, with its Dachen Medical Health Stock A fund holding 431,500 shares, accounting for 4.07% of the fund's net value [2] - The Dachen Medical Health Stock A fund has a current scale of 153 million yuan and has achieved a year-to-date return of 28.54%, ranking 1895 out of 4220 in its category [2] - The fund manager, Yang Ting, has been in the position for 11 years and 114 days, with the best fund return during his tenure being 77.63% [2]

Group 1 - The core point of the news is that Sichuan Huiyu Pharmaceutical Co., Ltd. experienced a stock decline of 6.24%, with the current share price at 20.00 CNY and a total market capitalization of 8.472 billion CNY [1] - The company specializes in the research, production, and sales of drugs in the oncology field and complex injectable drugs, with 97.27% of its revenue coming from drug sales [1] - The company was established on October 12, 2010, and went public on October 26, 2021 [1] Group 2 - From the perspective of fund holdings, Yongying Fund has a significant position in Huiyu Pharmaceutical, with its Yongying Medical Health A fund holding 219,600 shares, representing 3.56% of the fund's net value [2] - The fund has reported a floating loss of approximately 292,100 CNY as of the latest update [2] - Yongying Medical Health A fund has a total scale of 24.1775 million CNY and has achieved a year-to-date return of 18.06% [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688553 证券简称：汇宇制药 公告编号：2025-082 ● 近日，股东黄乾益先生分别被四川自由贸易试验区人民法院、四川省泸州市江阳区人民法院、浙江省 杭州市拱墅区人民法院轮候冻结合计6,070,738股。截至2025年10月9日，股东黄乾益先生累计被轮候冻 结股份数6,350,738股，占其所持股份比例为23.33%，占公司总股本比例为1.50%。 四川汇宇制药股份有限公司 持股5%以上股东股份被司法冻结及轮候冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 截至公告披露日，四川汇宇制药股份有限公司（以下简称"公司"）股东黄乾益直接持有公司股份 27,219,439股，占公司总股本比例为6.43%。 ● 近日，股东黄乾益先生所持公司股份被四川省泸州市江阳区人民法院司法冻结5,788,307股。截至2025 年10月9日，股东黄乾益先生累计司法冻结股份数27,219,439股，占其所持股份比例为100%，占公司总 股本比例为6.4 ...

Group 1 - The company Huayu Pharmaceutical (SH 688553) announced that shareholder Huang Qianyi's shares have been judicially frozen, with approximately 5.79 million shares frozen and about 6.07 million shares under pending freeze [1] - As of the announcement date, Huang Qianyi has a total of approximately 27.22 million frozen shares, accounting for 100% of his holdings and 6.43% of the company's total equity; additionally, he has about 6.35 million shares under pending freeze, representing 23.33% of his holdings and 1.5% of the company's total equity [1] - For the fiscal year 2024, Huayu Pharmaceutical's revenue composition is projected to be 99.18% from pharmaceuticals and 0.82% from other businesses [1] Group 2 - The current market capitalization of Huayu Pharmaceutical is 9 billion yuan [1]